Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
32.44
+0.45 (1.41%)
At close: Feb 10, 2026, 4:00 PM EST
32.38
-0.06 (-0.18%)
After-hours: Feb 10, 2026, 7:59 PM EST
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Stoke Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $34.5, which forecasts a 6.35% increase in the stock price over the next year. The lowest target is $24 and the highest is $50.
Price Target: $34.5 (+6.35%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 12, 2026.
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 7 | 8 | 8 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $32 → $36 | Buy | Maintains | $32 → $36 | +10.97% | Jan 12, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $24 → $35 | Strong Buy | Maintains | $24 → $35 | +7.89% | Jan 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $28 → $36 | Strong Buy | Maintains | $28 → $36 | +10.97% | Jan 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $35 → $50 | Strong Buy | Maintains | $35 → $50 | +54.13% | Dec 15, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $24 → $28 | Strong Buy | Maintains | $24 → $28 | -13.69% | Nov 5, 2025 |
Financial Forecast
Revenue This Year
193.33M
from 36.56M
Increased by 428.87%
Revenue Next Year
35.20M
from 193.33M
Decreased by -81.79%
EPS This Year
0.20
from -1.65
EPS Next Year
-3.12
from 0.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 209.7M | 73.5M | ||||
| Avg | 193.3M | 35.2M | ||||
| Low | 181.0M | 11.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 473.6% | -62.0% | ||||
| Avg | 428.9% | -81.8% | ||||
| Low | 395.2% | -93.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.45 | -2.42 | ||||
| Avg | 0.20 | -3.12 | ||||
| Low | 0.03 | -3.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.